Date of Award
1-1-2023
Document Type
Thesis
Degree Name
M.S. in Pharmaceutical Science
First Advisor
Soumyajit Majumdar
Second Advisor
Soumyajit Majumdar
Third Advisor
Mohammed Maniruzzaman
Relational Format
dissertation/thesis
Abstract
Ovarian cancer (OC) is the fifth-most common cause of cancer-related deaths among women. It is often difficult to detect in its early stages, leading to a higher mortality rate. There are several types of ovarian cancer, including epithelial ovarian cancer, germ cell ovarian cancer, and stromal ovarian cancer, which is the most common type among all of them. The exact causes of ovarian cancer are not fully understood. Paclitaxel (PTX), a chemotherapeutic agent, is currently used as the first-line agent in combined therapy for epithelial OC. Doxycycline (DOX) is a Tetracycline class of antibiotics, currently emerging as a chemotherapeutic agent due to its potential to inhibit MMPs. This current study involves the development of a nanoformulation that can deliver PTX and DOX using a single system. The lipids used in the formulation were selected based on their solubility with each drug. The processing parameters and the lipid ratios were selected to produce the desired Particle size, polydispersity index, and Zeta potential. Formulation stability was evaluated for their physio-chemical properties including drug content over 45 days at various temperatures.
Recommended Citation
Nalajala, Navya, "Development and characterization of an intravenous formulation containing Paclitaxel-loaded lipid nanoparticles and Doxycycline" (2023). Electronic Theses and Dissertations. 2762.
https://egrove.olemiss.edu/etd/2762